Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial

Overview of attention for article published in BMC Cancer, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 1 news outlet

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 8 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 1 news story.

Oral apatinib-etoposide combo may be administered in pretreated advanced TNBC (of 11)

Pediatric News , 16 Jun 2023

Key clinical point: The combination of apatinib and etoposide proved to be a feasible treatment option for patients with triple-n…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.